The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models

Clinical Cancer Research

Volumn 22, Issue 22, 2016, Pages 5527-5538

  Zhang, Sen ^a   Anjum, Rana ^a   Squillace, Rachel ^a   Nadworny, Sara ^a   Zhou, Tianjun ^a   Keats, Jeff ^a   Ning, Yaoyu ^a   Wardwell, Scott D ^a   Miller, David ^a   Song, Youngchul ^a   Eichinger, Lindsey ^a   Moran, Lauren ^a   Huang, Wei Sheng ^a   Liu, Shuangying ^a   Zou, Dong ^a   Wang, Yihan ^a   Mohemmad, Qurish ^a   Jang, Hyun Gyung ^a   Ye, Emily ^a   Narasimhan, Narayana ^a   Wang, Frank ^a   Miret, Juan ^a   Zhu, Xiaotian ^a   Clackson, Tim ^a   Dalgarno, David ^a   Shakespeare, William C ^a   Rivera, Victor M ^a   more..

^a ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALECTINIB; BRIGATINIB; CERITINIB; CRIZOTINIB; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; ORGANOPHOSPHORUS COMPOUND; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENCY; FEMALE; IC50; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; HEP-G2 CELL LINE; HUMAN; LUNG TUMOR; METABOLISM; MUTATION; NON SMALL CELL LUNG CANCER; TUMOR CELL LINE; U-937 CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HEP G2 CELLS; HUMANS; LUNG NEOPLASMS; MUTATION; ORGANOPHOSPHORUS COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONES; U937 CELLS;

EID: 84995934724     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0569     Document Type: Article

References (36)

1. Grande E, Bolós M-V, Arriola E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther 2011;10:569-79.
2. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
3. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. Firstline crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77.
4. Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigmfor precision cancer medicine. Clin Cancer Res 2015;21:2227-35.
5. Toyokawa G, Seto T. Updated evidence on themechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data. Oncol Res Treat 2015;38:291-8.
6. Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PAJr, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012;7:1807-14.
7. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 2015; 33:1881-8.
8. Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4:662-73.
9. Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011;19:679-90.
10. Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014;15:1119-28.
11. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014; 370:1189-97.
12. Ou SI, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 2016;34:661-8.
13. Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, et al. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Lung Cancer 2015;88:231-4.
14. Ou SH, Klempner SJ, Greenbowe JR, Azada M, Schrock AB, Ali SM, et al. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. J Thorac Oncol 2014;9:1821-5.
15. Ou SH, Milliken JC, Azada MC, Miller VA, Ali SM, Klempner SJ. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. Lung Cancer 2016;91:70-2.
16. Iwama E, Okamoto I, Harada T, Takayama K, Nakanishi Y. Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. Onco Targets Ther 2014;7:375-85.
17. Hatcher JM, Bahcall M, Choi HG, Gao Y, Sim T, George R, et al. Discovery of inhibitors that overcome the G1202R anaplastic lymphoma kinase resistance mutation. J Med Chem 2015;58:9296-308.
18. Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res 2015;21:166-74.
19. Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med 2016;374:54-61.
20. Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 2014;20:5686-96.
21. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.
22. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51.
23. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369:1783-96.
24. Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, et al. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood 2016;127:703-12.
25. Smith MA, Houghton P. A proposal regarding reporting of in vitro testing results. Clin Cancer Res 2013;19:2828-33.
26. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997;14:439-49.
27. Zhang S, Nadworny S, Wardwell SD, Eichinger L, Das B, Emily YY, et al. The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first-and second-generation ALK TKIs in preclinical models. Cancer Res 2015;75:781.
28. Fontana D, Ceccon M, Gambacorti-Passerini C, Mologni L. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. Cancer Med 2015;4:953-65.
29. Ceccon M, Mologni L, Giudici G, Piazza R, Pirola A, Fontana D, et al. Treatment efficacy and resistancemechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma. Mol Cancer Res 2015;13:775-83.
30. Huang WS, Liu S, Zou D, Thomas M, Wang Y, Zhou T, et al. Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase. J Med Chem 2016;59:4948-64.
31. Gettinger SN, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, et al. Brigatinib (AP26113) efficacy and safety in ALK+ NSCLC: phase 1/2 trial results. J Thorac Oncol;10:S238.
32. Gehrke BJ. Clinical pharmacology review. Xalkori, crizotinib. Center for Drug Evaluation and Research: U.S. Food and Drug Administration; 2011. Report No.: 202570.
33. Brigatinib (data on file). ARIAD Pharmaceuticals, Inc.
34. Ou S, Gadgeel S, Chiappori A, Riely G, Lee R, Garcia L, et al. Safety and efficacy analysis of RO5424802/CH5424802 in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients who have failed crizotinib in a dose-finding phase I study (AF-002JG, NCT01588028). Eur J Cancer 2013;49:S19.
35. Brower M, Fox E. Clinical pharmacology review. Zykadia, ceritinib. Center for Drug Evaluation and Research: U.S. Food and Drug Administration; 2014. Report No.: 205755.
36. Zahalka E, Ringgold K. Clinical pharmacology review. Alecensa, alectinib. Center for Drug Evaluation and Research: U.S. Food and Drug Administration; 2015. Report No.: 208434.